Quoin Pharmaceuticals (QNRX) Common Equity (2018 - 2026)

Quoin Pharmaceuticals has disclosed Common Equity across 9 years of filings, most recently posting $3.9 million for Q2 2026.

• In Q2 2026, Common Equity rose 54.14% year-over-year to $3.9 million; the TTM figure through Jun 2026 stood at $3.9 million (up 54.14% YoY), while the FY2025 annual figure was $13.1 million, up 42.54% from the prior year.
• Common Equity came in at $3.9 million for Q2 2026 at Quoin Pharmaceuticals, down from $8.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $13.1 million in Q4 2025 to a low of -$3.2 million in Q2 2022.
• Average Common Equity over 5 years is $6.1 million, with a median of $7.4 million recorded in 2022.
• Year-over-year, Common Equity jumped 1596.34% in 2023 and plunged 122.32% in 2025.
• Over 5 years, Common Equity stood at $7.4 million in 2022, then decreased by 23.53% to $5.7 million in 2023, then jumped by 62.51% to $9.2 million in 2024, then soared by 42.54% to $13.1 million in 2025, then plunged by 70.03% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $3.9 million in Q2 2026, $8.8 million in Q1 2026, and $13.1 million in Q4 2025.